Doug Besch - Oct 3, 2022 Form 4 Insider Report for OptimizeRx Corp (OPRX)

Role
Chief Product Officer
Signature
/s/ Marion Odence-Ford, by Power of Attorney
Stock symbol
OPRX
Transactions as of
Oct 3, 2022
Transactions value $
$0
Form type
4
Date filed
10/5/2022, 01:14 PM
Previous filing
Oct 3, 2022
Next filing
Oct 6, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OPRX Restricted Stock Units Award $0 +9.97K $0.00 9.97K Oct 3, 2022 Common Stock 9.97K Direct F1, F2
transaction OPRX Stock Option Award $0 +19.5K $0.00 19.5K Oct 3, 2022 Common Stock 19.5K $15.04 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock.
F2 The restricted stock units vest in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date.
F3 The stock option vests in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.